Alleviant Medical is a clinical stage medical device company founded in 2017 that has developed a minimally invasive system to treat patients suffering from chronic heart failure who are symptomatic despite appropriate medical therapy. The company has conducted successful first in human studies and is currently enrolling in its global pivotal trial, ALLAY-HF.
The Alleviant’s system is designed to create a connection between the left and right atrial chambers of the heart through a single procedure without leaving a permanent implant behind. The procedure is intended to reduce excess pressure buildup within the heart, which may reduce symptoms of heart failure such as shortness of breath, fatigue and weakness.
In 2024, Gilde invested in Alleviant Medical to advance the company’s clinical development plan, facilitating potential FDA approval and bring its innovative solution to market, improving the lives of millions of heart failure patients.